About Candel Therapeutics
Candel Therapeutics is a company based in United States founded in 1999.. Candel Therapeutics has raised $110.3 million across 14 funding rounds from investors including HHS, Sands Capital Ventures and Northpond Ventures. The company has 38 employees as of December 31, 2024. Candel Therapeutics offers products and services including CAN-2409 and CAN-3110. Candel Therapeutics operates in a competitive market with competitors including Replimune, TScan Therapeutics, Lyell Immunopharma, Hummingbird Bioscience and GigaGen, among others.
- Headquarter United States
- Employees 38 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Candel Therapeutics, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-55.18 M-45.44as on Dec 31, 2024
-
EBITDA
$-32.38 M12.93as on Dec 31, 2024
-
Total Equity Funding
$110.3 M (USD)
in 14 rounds
-
Latest Funding Round
$22.5 M (USD), Series C
Apr 01, 2019
-
Investors
HHS
& 5 more
-
Employee Count
38
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Candel Therapeutics
Candel Therapeutics is a publicly listed company on the NASDAQ with ticker symbol CADL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Candel Therapeutics
Candel Therapeutics offers a comprehensive portfolio of products and services, including CAN-2409 and CAN-3110. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Mechanism of action for targeted cancer treatment using viral agents.
Another viral mechanism designed for cancer immunotherapy applications.
Unlock access to complete
Unlock access to complete
Leadership Team
19 people
Scientific Team
8 people
Clinical Team
6 people
Research Team
5 people
Data Analysis and Operations Team
4 people
Software Development Team
3 people
Senior Team
3 people
Human Resources and Administration
2 people
Unlock access to complete
Funding Insights of Candel Therapeutics
Candel Therapeutics has successfully raised a total of $110.3M across 14 strategic funding rounds. The most recent funding activity was a Series C round of $22.5 million completed in April 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 14
- Last Round Series C — $22.5M
-
First Round
First Round
(07 Jun 2004)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2019 | Amount | Series C - Candel Therapeutics | Valuation |
investors |
|
| Jan, 2019 | Amount | Series B - Candel Therapeutics | Valuation | PBM Capital |
|
| Nov, 2018 | Amount | Series B - Candel Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Candel Therapeutics
Candel Therapeutics has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Sands Capital Ventures and Northpond Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Growth stage tech & life sciences focused VC Firm investing in Asia and the US
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in life sciences & tech sectors
|
Founded Year | Domain | Location | |
|
PE firm investing in the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Candel Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Candel Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Candel Therapeutics Comparisons
Competitors of Candel Therapeutics
Candel Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Replimune, TScan Therapeutics, Lyell Immunopharma, Hummingbird Bioscience and GigaGen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of oncolytic immunotherapies
|
|
| domain | founded_year | HQ Location |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| domain | founded_year | HQ Location |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| domain | founded_year | HQ Location |
Antibody drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
|
| domain | founded_year | HQ Location |
An immunotherapy platform for oncology and other diseases is developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Candel Therapeutics
Frequently Asked Questions about Candel Therapeutics
When was Candel Therapeutics founded?
Candel Therapeutics was founded in 1999 and raised its 1st funding round 5 years after it was founded.
Where is Candel Therapeutics located?
Candel Therapeutics is headquartered in United States.
Who is the current CEO of Candel Therapeutics?
Aguilar Estuardo is the current CEO of Candel Therapeutics.
Is Candel Therapeutics a funded company?
Candel Therapeutics is a funded company, having raised a total of $110.3M across 14 funding rounds to date. The company's 1st funding round was a Series B of $28.7M, raised on Jun 07, 2004.
How many employees does Candel Therapeutics have?
As of Dec 31, 2024, the latest employee count at Candel Therapeutics is 38.
What does Candel Therapeutics do?
Candel Therapeutics was founded in 1999 in the United States. Focus is placed on the biotechnology sector, where viral immunotherapies are created to target cancer. These therapies work by lysing tumor cells to release antigens and neoantigens, which trigger in situ vaccination and activate both innate and adaptive immune responses. Operations center on research and development of such immunotherapies, with leadership provided by CEO Aguilar Estuardo.
Who are the top competitors of Candel Therapeutics?
Candel Therapeutics's top competitors include Hummingbird Bioscience, Replimune and Lyell Immunopharma.
What products or services does Candel Therapeutics offer?
Candel Therapeutics offers CAN-2409 and CAN-3110.
Is Candel Therapeutics publicly traded?
Yes, Candel Therapeutics is publicly traded on NASDAQ under the ticker symbol CADL.
Who are Candel Therapeutics's investors?
Candel Therapeutics has 6 investors. Key investors include HHS, Sands Capital Ventures, Northpond Ventures, PBM Capital, and National Securities Corporation.
What is Candel Therapeutics's ticker symbol?
The ticker symbol of Candel Therapeutics is CADL on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.